Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept + sirolimus islet transplant study for hypoglycaemia unawareness
ACTRN12619000268145Phase 2Recruiting
- Sponsor
- The University of Sydney
- Start
- May 2019
- Modality
- Small Molecules, Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of belatacept, sirolimus, antithymocyte globulin, mycophenolate mofetil and basiliximab in diabetes mellitus type 1 (T1D) (2 arms), sponsored by The University of Sydney. Primary endpoint: Freedom from hypoglycaemia with graft function and glycaemic control. Started May 2019; status: recruiting.
02
Drugs
belataceptsirolimusantithymocyte globulinmycophenolate mofetilbasiliximab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12619000268145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000268145.